[go: up one dir, main page]

NO20091243L - Bifeprunox titration scheme for the treatment of schizophrenia and kits for use therein - Google Patents

Bifeprunox titration scheme for the treatment of schizophrenia and kits for use therein

Info

Publication number
NO20091243L
NO20091243L NO20091243A NO20091243A NO20091243L NO 20091243 L NO20091243 L NO 20091243L NO 20091243 A NO20091243 A NO 20091243A NO 20091243 A NO20091243 A NO 20091243A NO 20091243 L NO20091243 L NO 20091243L
Authority
NO
Norway
Prior art keywords
bifeprunox
treatment
titration scheme
schizophrenia
kits
Prior art date
Application number
NO20091243A
Other languages
Norwegian (no)
Inventor
Antje A Winsemius
Pieter W A J Van Den Broeck
Luigi M Barbato
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20091243L publication Critical patent/NO20091243L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives anvendelsen av en bifeprunox forbindelse for et titreringssett for et titreringsopplegg for å lette initiering av behandling av minst en sentralnervesystem tilstand eller forstyrrelse ved administrering av et antall doseringsenheter som omfatter en forbindelse 7-[4-([1,1'-bifenyl]-3-ylmetyl)-l-piperazinyl]-2(3H)-benzoksazolon monometan-sulfonat (INN bifeprunox).The use of a bifeprunox compound for a titration scheme titration scheme is described to facilitate initiation of treatment of at least one central nervous system condition or disorder by administering a plurality of dosage units comprising a compound 7- [4 - ([1,1'-biphenyl]). -3-ylmethyl) -1-piperazinyl] -2 (3H) -benzoxazolone monomethanesulfonate (INN bifeprunox).

NO20091243A 2006-08-31 2009-03-25 Bifeprunox titration scheme for the treatment of schizophrenia and kits for use therein NO20091243L (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84124406P 2006-08-31 2006-08-31
EP06119936 2006-08-31
US84149506P 2006-09-01 2006-09-01
EP06120016 2006-09-01
PCT/EP2007/058957 WO2008025780A1 (en) 2006-08-31 2007-08-29 Titration schedule for bifeprunox for treating schizophrenia and kits for use therein

Publications (1)

Publication Number Publication Date
NO20091243L true NO20091243L (en) 2009-03-25

Family

ID=38704953

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091243A NO20091243L (en) 2006-08-31 2009-03-25 Bifeprunox titration scheme for the treatment of schizophrenia and kits for use therein

Country Status (10)

Country Link
EP (2) EP2059244A1 (en)
JP (2) JP2010501625A (en)
KR (1) KR20090063228A (en)
AU (2) AU2007291235A1 (en)
BR (1) BRPI0715445A2 (en)
CA (2) CA2661120A1 (en)
EA (1) EA200970239A1 (en)
IL (1) IL196867A0 (en)
NO (1) NO20091243L (en)
WO (2) WO2008025781A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060742A1 (en) * 2008-11-03 2010-06-03 Solvay Pharmaceuticals B.V. Combination of bifeprunox and an antipsychotic drug with d2/5-ht2a receptor antagonistic activity for treating cns disorders
WO2010070061A1 (en) * 2008-12-19 2010-06-24 Abbott Healthcare Products B.V. Compositions, kits and methods of a titration schedule for bifeprunox compounds
HRP20171415T4 (en) * 2009-06-25 2023-03-03 Alkermes Pharma Ireland Limited HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
CA2885196C (en) 2012-09-19 2021-06-22 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
JP6524110B2 (en) 2014-03-20 2019-06-05 アルカームス ファーマ アイルランド リミテッド Aripiprazole formulations with increased injection rates
JP7384812B2 (en) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド Aripiprazole dosing strategy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ331860A (en) 1996-03-29 2000-04-28 Duphar Int Res Piperazine and piperidine compounds with affinity for both dopamine D2 and seratonin 5-HT1A receptors
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects
AR034206A1 (en) 2001-02-16 2004-02-04 Solvay Pharm Bv A PROCEDURE FOR THE PREPARATION OF MESILATES OF PIPERAZINE DERIVATIVES AND SUCH MESILATES
AR045362A1 (en) * 2003-08-18 2005-10-26 Solvay Pharm Bv STABLE CRYSTALLINE FORM OF BIFEPRUNOX MESILATE (MONOMETANSULFONATE 7- [4 - ([1,1- BIFENIL] -3- ILMETIL) -1- PIPERAZINIL] - 2- (3H) -BENZOXAZOLONA
US7423040B2 (en) * 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
WO2007023141A1 (en) 2005-08-22 2007-03-01 Solvay Pharmaceuticals B.V. N-oxides as prodrugs of piperazine & piperidine derivatives

Also Published As

Publication number Publication date
EA200970239A1 (en) 2009-08-28
WO2008025780A1 (en) 2008-03-06
BRPI0715445A2 (en) 2014-05-13
CA2661120A1 (en) 2008-03-06
KR20090063228A (en) 2009-06-17
AU2007291235A1 (en) 2008-03-06
EP2059245A1 (en) 2009-05-20
AU2007291234A1 (en) 2008-03-06
WO2008025781A1 (en) 2008-03-06
IL196867A0 (en) 2009-11-18
JP2010501626A (en) 2010-01-21
EP2059244A1 (en) 2009-05-20
JP2010501625A (en) 2010-01-21
CA2661800A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
NO20091243L (en) Bifeprunox titration scheme for the treatment of schizophrenia and kits for use therein
DOP2010000165A (en) 4- (4-CIANO-2-TIOARIL) DIHYDROPIRIMIDINONES AND ITS USE AS INHIBITORS OF THE HUMAN NEUTROPHYL ELASTASE
NO20080675L (en) P38-Map kinase inhibitors and methods for their use
MA30652B1 (en) ORGANIC COMPOUNDS
BRPI0417260A (en) azepinoindole derivatives as pharmaceutical agents
BR0310106A (en) Compound, process for producing a compound, pharmaceutical composition, use of the compound and method for treating a subject suffering from a pathological condition or disease
DE50311898D1 (en) FREDERICAMYCIN DERIVATIVES AS A MEDICAMENT FOR TUMOR TREATMENT
NO20091893L (en) New 1,4-benzothiepine-1,1-dioxide derivatives substituted with benzyl groups, processes for the preparation of medicaments containing the compounds and their use.
EA201270666A1 (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING URIC ACID LEVEL
MA34361B1 (en) TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES
BRPI0515482A (en) heterocyclic derivatives and their uses as therapeutic agents
NO20090755L (en) Amino-imidazolones and their use as a drug for the treatment of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia
BRPI0720551A2 (en) compound or a pharmaceutically acceptable salt thereof, and, use thereof, method for treating cancer, processes for preparing a pharmaceutical composition and a compound or a pharmaceutically acceptable salt thereof
NO20011721L (en) N-aralkylaminotetralins as ligands for the neuropeptide Y Y5 receptor
MX2010002115A (en) 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders.
UY28931A1 (en) USED PIRROLOTRIAZINE DERIVATIVES TO TREAT HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
GEP20125538B (en) 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
DE60206911D1 (en) IMIDAZOLE-2-CARBOXYLAMIDE DERIVATIVES AS RAF KINASE INHIBITORS
MA37886B1 (en) New bicyclic pyridinones
BRPI0806789B8 (en) compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and, use of a compound or a pharmaceutically acceptable salt thereof
ATE327225T1 (en) NEW USE OF BENZOTHIAZOLE DERIVATIVES
NO20083036L (en) Use of benzofused heterocyclic sulfamide derivatives for the treatment of depression
NO20090266L (en) Piperazinyl derivatives useful in the treatment of GPR38 receptor-mediated diseases
CL2007000595A1 (en) Piperidine derived compounds; Pharmaceutical composition and use for the treatment and / or prophylaxis of diseases selected from hypertension, congestive heart failure and renal failure, among others.
MX2008013017A (en) TREATMENT OF HEMATOLOGICAL EVILUATIONS WITH FTS AND A BCR-ABL THYROSINE KINASE INHIBITOR.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application